Related Experiment Video
Updated: Feb 9, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
Let‑7d inhibits colorectal cancer cell proliferation through the CST1/p65 pathway
Jie Jiang1, Hui-Ling Liu1, Li Tao1
1Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, P.R. China.
Abstract:
Cystatin SN (cystatin 1, CST1) is a member of the cystatin superfamily which inhibits the proteolytic activity of cysteine proteases. CST1 is a tumor biomarker that provides useful information for the diagnosis of esophageal, gastric and colorectal carcinomas. MicroRNAs (miRNAs or miRs) play an important role in tumor cell proliferation. However, the exact role of let‑7d and CST1 in colon cancer remains unknown. The aim of this study was to assess whether let‑7d inhibits colorectal carcinogenesis through the CST1/p65 pathway, and determine whether it may be used as a potential target for clinical therapy. Microarray analysis of mRNAs extracted from colon cancer and normal tissues was performed. The results of gene expression microanalysis revealed that CST1 expression was upregulated in colon cancer compared with normal tissues. In addition, the upregulation of CST1 expression and the downregulation of let‑7d expression in patients with colon cancer and in several colorectal cancer cell lines were confirmed by reverse transcription-quantitative PCR (RT‑qPCR), immunohistochemistry and western blot analysis. In addition, siRNA targeting CST1 (CST1‑siRNA) and let‑7d-mimics were used in the HCT116 cells, and the results revealed that CST1 and let‑7d played a role in colorectal cancer cell proliferation. Let‑7d inhibited colorectal carcinogenesis through the CST1/p65 pathway. Thus, the findings of the present study indicate that CST1 may be a potential target for the future clinical therapy of colorectal cancer.
Insights
MicroRNA let-7d inhibits colorectal cancer progression by downregulating Cystatin SN (CST1) via the CST1/p65 pathway. This finding suggests CST1 as a potential therapeutic target for colon cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cystatin SN (CST1) is a cysteine protease inhibitor and a known tumor biomarker for various carcinomas.
- MicroRNAs (miRNAs) are crucial regulators of tumor cell proliferation, but the specific roles of let-7d and CST1 in colon cancer are not fully understood.
Purpose of the Study:
- To investigate if let-7d inhibits colorectal carcinogenesis through the CST1/p65 pathway.
- To determine the potential of let-7d and CST1 as clinical therapeutic targets for colorectal cancer.
Main Methods:
- Microarray analysis of mRNA from colon cancer and normal tissues.
- Reverse transcription-quantitative PCR (RT-qPCR), immunohistochemistry, and western blot analysis to confirm gene and protein expression.
- Use of siRNA targeting CST1 (CST1-siRNA) and let-7d-mimics in HCT116 cells.
Main Results:
- CST1 expression was significantly upregulated in colon cancer tissues and cell lines compared to normal tissues.
- let-7d expression was downregulated in colon cancer patients and cell lines.
- let-7d demonstrated an inhibitory effect on colorectal cancer cell proliferation by targeting the CST1/p65 pathway.
Conclusions:
- let-7d inhibits colorectal carcinogenesis through the CST1/p65 pathway.
- CST1 represents a potential therapeutic target for future clinical interventions in colorectal cancer treatment.
Related Concept Videos
Feedback Inhibition
Cells Coordinate Growth and Proliferation
Abnormal Proliferation
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Enzyme Inhibition
Inhibition of Cdk Activity

